Amol Akhade, A Senior Consultant Medical Oncologist and Hemato-oncologist at Suyog Cancer Clinics and Reliance Hospitals shared a post on LinkedIn:
“Mariposa shows significant OS benifit .
Median OS Improved by more than one year.
Press release.
Considering toxicity of Amivantamab plus Lazertinib, now with OS data, will u change the practice?
It will be intresting to see final data once presented.”
